NCT06916494View on ClinicalTrials.gov

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

January 20, 2026

Study Completion Date

January 20, 2026

Conditions
Muscle Invasive Bladder Cancer
Interventions
DRUG

Rutin

Rutin 40 mg tid. Treatment will be given for 2 cycles (21 days per cycle)

DRUG

Gemcitabine, Cisplatin

Cisplatin 100 mg/m² D2 q3w, and Gemcitabine 1000 mg/m² D1, D8 q3w. Treatment will be given for 2 cycles (21 days per cycle)

DRUG

Tislelizumab

Tislelizumab 200 mg D1 q3w Treatment will be given for 2 cycles (21 days per cycle)

Trial Locations (1)

Unknown

RECRUITING

First Affiliated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors
lead

First Affiliated Hospital of Chongqing Medical University

OTHER